COVID-19 Pandemic Hampering Launch of New Oncology Trials
A team of researchers conducted a study to assess the impact of the COVID-19 pandemic on the initiation of clinical trials in oncology.
A team of researchers conducted a study to assess the impact of the COVID-19 pandemic on the initiation of clinical trials in oncology.
Investigators measured responses to endocrine therapy by monitoring the change in tumor uptake of the progestin analog 21-[18F] fluorofuranylnorprogesterone (FFNP) before and after a 1-day estradiol challenge.
Sharma et al investigated whether reductions in prostate-specific antigen (PSA) screening were responsible for increased metastatic prostate cancer diagnoses in the United States.
Investigators of this real-world analysis studied survival trends among patients with muscle-invasive bladder cancer (MIBC) and patients with metastatic urothelial carcinoma (UC).
Investigators of this single-center analysis compare the incidence of CRLF2 rearrangement and IKZF1 deletion in Hispanic/Latino vs non-Hispanic/Latino children with B-cell acute lymphoblastic leukemia (B-ALL).
Bernstam et al presented findings from an expansion cohort of a phase 1 trial testing the bispecific HER2-targeted antibody zanidatamab in patients with HER2-overexpressing biliary tract cancer.
Investigators reviewed data from 202,237 patients from the Surveillance, Epidemiology, and End Results (SEER) registry who had been diagnosed CRC with 2010 and 2015.
Investigators developed a clinical score to address how to categorize patients with well-differentiated neuroendocrine tumors (NETs) who are being considered for peptide receptor radionuclide therapy (PRRT) and how to sequence therapy.
The average spending per hospitalization during the course of 5 years was higher for survivors of NHL compared with controls ($16,950 vs. $13,474).
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.